Literature DB >> 23983929

Aripiprazole use combined with depot antipsychotic medication: two cases demonstrating its ability to reduce prolactin levels in an adolescent forensic hospital.

Simon A Hill1, Al Aditya Khan, Marion Wetherill.   

Abstract

Many patients maintained on depot medication have raised prolactin levels, which can lead to a range of long-term medical problems. The addition of aripiprazole can reduce prolactin levels and restore sexual function in these patients. The cases described demonstrate the potential role of aripiprazole in a forensic setting.

Entities:  

Keywords:  antipsychotic; aripiprazole; forensic; hyperprolactinaemia; polypharmacy; prolactin

Year:  2011        PMID: 23983929      PMCID: PMC3736893          DOI: 10.1177/2045125311409284

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  17 in total

Review 1.  Practice guideline for the treatment of patients with schizophrenia, second edition.

Authors:  Anthony F Lehman; Jeffrey A Lieberman; Lisa B Dixon; Thomas H McGlashan; Alexander L Miller; Diana O Perkins; Julie Kreyenbuhl
Journal:  Am J Psychiatry       Date:  2004-02       Impact factor: 18.112

2.  Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.

Authors:  Felipe F Casanueva; Mark E Molitch; Janet A Schlechte; Roger Abs; Vivien Bonert; Marcello D Bronstein; Thierry Brue; Paolo Cappabianca; Annamaria Colao; Rudolf Fahlbusch; Hugo Fideleff; Moshe Hadani; Paul Kelly; David Kleinberg; Edward Laws; Josef Marek; Maurice Scanlon; Luis G Sobrinho; John A H Wass; Andrea Giustina
Journal:  Clin Endocrinol (Oxf)       Date:  2006-08       Impact factor: 3.478

3.  Resolution of haloperidol-induced hyperprolactinemia with aripiprazole.

Authors:  Raymond A Lorenz; Benjamin Weinstein
Journal:  J Clin Psychopharmacol       Date:  2007-10       Impact factor: 3.153

Review 4.  Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences.

Authors:  Gerald A Maguire
Journal:  J Clin Psychiatry       Date:  2002       Impact factor: 4.384

5.  Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.

Authors:  Stephen R Marder; Robert D McQuade; Elyse Stock; Stephen Kaplita; Ronald Marcus; Allan Z Safferman; Anutosh Saha; Mirza Ali; Taro Iwamoto
Journal:  Schizophr Res       Date:  2003-06-01       Impact factor: 4.939

6.  Aripiprazole and haloperidol: beneficial combination antipsychotic therapy for a schizophrenic patient.

Authors:  Joseph Kuo; Hai-Gwo Hwu
Journal:  Clin Neuropharmacol       Date:  2008 May-Jun       Impact factor: 1.592

7.  Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.

Authors:  Joo-Cheol Shim; Jae-Goo K Shin; Deanna L Kelly; Do-Un Jung; Young-Soo Seo; Kwang-Hyeon Liu; Ji-Hong Shon; Robert R Conley
Journal:  Am J Psychiatry       Date:  2007-09       Impact factor: 18.112

8.  Subjective utility ratings of neuroleptics in treating schizophrenia.

Authors:  S E Finn; J M Bailey; R T Schultz; R Faber
Journal:  Psychol Med       Date:  1990-11       Impact factor: 7.723

9.  The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.

Authors:  Troy A Moore; Robert W Buchanan; Peter F Buckley; John A Chiles; Robert R Conley; M Lynn Crismon; Susan M Essock; Molly Finnerty; Stephen R Marder; Del D Miller; Joseph P McEvoy; Delbert G Robinson; Nina R Schooler; Steven P Shon; T Scott Stroup; Alexander L Miller
Journal:  J Clin Psychiatry       Date:  2007-11       Impact factor: 4.384

Review 10.  Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects.

Authors:  U Halbreich; B J Kinon; J A Gilmore; L S Kahn
Journal:  Psychoneuroendocrinology       Date:  2003-01       Impact factor: 4.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.